Ublituximab as Relapsing MS Therapy Under FDA Review

Ublituximab as Relapsing MS Therapy Under FDA Review

314363

Ublituximab as Relapsing MS Therapy Under FDA Review

The U.S. Food and Drug Administration (FDA) has agreed to review TG Therapeutics’ application seeking the approval of ublituximab as a treatment for people with relapsing forms of multiple sclerosis. An FDA’s decision is expected on or before Sept. 28. The agency is not currently planning to hold an advisory committee meeting to discuss the application. Such meetings are held to seek the advice of an independent panel of experts when the FDA has questions or…

You must be logged in to read/download the full post.